1830:TADAWULLeejam Sports Company Analysis
Data as of 2026-05-26 - not real-time
HK$1.20
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Perfect Medical Health Management Limited trades around HKD 1.20, well below its DCF fair value of HKD 2.08, indicating a sizable valuation gap. The stock’s PE ratio of 9.2x is markedly lower than the industry average of 27.6x**, suggesting it is priced on a discount basis. However, revenue has contracted by 21.7% year‑over‑year, raising concerns about growth momentum. The company boasts strong profitability metrics—gross margin above 60% and ROE near 38%—and generates robust cash flow, yet it carries a high dividend payout ratio of roughly 129%, making the current 12.5% dividend yield potentially unsustainable. Technical indicators are mixed: the MACD has turned bearish, RSI hovers around 49, and volume trends are decreasing, placing the price near its identified support of HKD 1.16. Overall, the stock appears undervalued but faces near‑term pressure from earnings decline and dividend sustainability concerns.
From a risk perspective, the equity exhibits low market sensitivity with a beta under 0.5 and moderate 30‑day volatility around 30%, while liquidity is tightening as trading volumes slip. Healthcare sector exposure adds a medium level of regulatory and geographic risk given operations across Hong Kong, mainland China, and other Asian markets. The combination of a strong balance sheet, attractive valuation, and significant upside potential in the DCF model supports a longer‑term bullish stance, though investors should remain cautious of short‑term price pressure and dividend policy risks.
From a risk perspective, the equity exhibits low market sensitivity with a beta under 0.5 and moderate 30‑day volatility around 30%, while liquidity is tightening as trading volumes slip. Healthcare sector exposure adds a medium level of regulatory and geographic risk given operations across Hong Kong, mainland China, and other Asian markets. The combination of a strong balance sheet, attractive valuation, and significant upside potential in the DCF model supports a longer‑term bullish stance, though investors should remain cautious of short‑term price pressure and dividend policy risks.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram
- Decreasing trading volume
- Price near technical support level
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Low PE relative to industry
- Strong cash generation and low debt
- Potential upside to DCF fair value
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation upside
- Stable earnings margins and high ROE
- Low beta and sector stability
Key Metrics & Analysis
Financial Health
Revenue Growth-21.70%
Profit Margin16.19%
P/E Ratio9.2
ROE38.33%
ROA12.53%
Debt/Equity41.82
P/B Ratio3.5
Op. Cash FlowHK$285.7M
Free Cash FlowHK$182.2M
Industry P/E27.6
Technical Analysis
TrendNeutral
RSI49.1
SupportHK$1.16
ResistanceHK$1.25
MA 20HK$1.21
MA 50HK$1.19
MA 200HK$1.34
MACDBearish
VolumeDecreasing
Fear & Greed Index91.8
Valuation
Fair ValueHK$2.08
GradeUndervalued
TypeValue
Dividend Yield12.46%
Risk Assessment
Beta0.44
Volatility29.70%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.